How RNA and iron regulation influence early mammalian development
POST-TRANSCRIPTIONAL REGULATION OF CELL FATE IN EARLY MAMMALIAN DEVELOPMENT
This study is looking at how certain proteins and tiny molecules help decide what cells become during early development in mammals, which could lead to new ways to improve treatments for conditions like nerve or gut issues.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11056167 on NIH RePORTER |
What this research studies
This research investigates the role of RNA-binding proteins and microRNAs in regulating cell fate during early mammalian development. By focusing on how these molecules interact with iron regulatory proteins, the study aims to uncover their importance in processes like neurogenesis and gut development. The research employs advanced molecular biology techniques to explore these interactions and their implications for stem cell therapies. Understanding these mechanisms could lead to new strategies for manipulating cell fate in regenerative medicine.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals with conditions related to developmental disorders or those interested in stem cell therapies.
Not a fit: Patients with fully developed and stable conditions unrelated to early development or stem cell therapies may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies for developmental disorders and enhance regenerative medicine approaches.
How similar studies have performed: Other research has shown promising results in understanding RNA regulation in development, suggesting that this approach could yield significant insights.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Sangokoya, Carolyn O — University of California, San Francisco
- Study coordinator: Sangokoya, Carolyn O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.